Yeah but at at least they are chipping in the Keytruda, which isn't cheap. If thru ate looking to have say 300 patients and its costs $130k(?)per annum to be on the stuff....
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game